{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-000957","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.651472+00:00","generated_at":"2026-05-26T09:59:52.435345+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aptose gets CSRC approval to escalate TUS dose; CRs seen in difficult AML","bullets":["CSRC unanimously approves dose escalation from 40 mg to 80 mg of tuspetinib in TUSCANY trial of TUS+VEN+AZA triplet.","Four patients dosed at 40 mg; no DLTs or prolonged myelosuppression; all remain on study.","Two FLT3-WT patients achieved CR/CRh; one patient with biallelic TP53 mutations and complex karyotype achieved CR.","Enrollment open for 80 mg cohort; 18-24 patients expected by mid-late 2025.","PK shows TUS plasma levels unaffected by AZA; VEN levels consistent with prior studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-000957","json":"https://secwatch.observer/filing/0001171843-25-000957.json","markdown":"https://secwatch.observer/filing/0001171843-25-000957.md","text":"https://secwatch.observer/filing/0001171843-25-000957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325000957/0001171843-25-000957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325000957/f8k_022025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T09:59:52.435345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}